Vilitra is a prescription medication containing Vardenafil, a potent PDE5 inhibitor clinically proven to manage erectile dysfunction (ED). It functions by enhancing blood flow to the penile tissues, facilitating a firm and sustainable erection when sexual stimulation occurs. This medication is designed for adult men experiencing difficulties in achieving or maintaining an erection sufficient for satisfactory sexual performance. Vilitra offers a reliable therapeutic option, with various dosage strengths available to tailor treatment to individual patient needs and response.

Features

• Active ingredient: Vardenafil (10mg, 20mg, 40mg, 60mg tablets)
• Rapid onset of action, typically within 25-60 minutes
• Long duration of efficacy, up to 4-5 hours
• High selectivity for phosphodiesterase type 5 (PDE5)
• Film-coated tablets for ease of administration
• Manufactured under strict GMP guidelines

Benefits

• Restores the ability to achieve and maintain erections sufficient for sexual intercourse.
• Improves confidence and reduces anxiety related to sexual performance.
• Enhances overall sexual satisfaction for both partners.
• Offers flexibility in sexual activity due to its extended window of effectiveness.
• Supports psychological well-being by addressing a key aspect of male sexual health.
• Provides a dose-responsive treatment, allowing for individualized therapy.

Common use

Vilitra is primarily prescribed for the treatment of erectile dysfunction in adult men. It is suitable for patients with various underlying etiologies of ED, including vasculogenic, neurogenic, and psychogenic origins. It may be used in cases of diabetes-related ED or post-prostatectomy erectile difficulties, following thorough medical evaluation. It is not indicated for use in women, children, or adolescents.

Dosage and direction

The recommended starting dose is 10mg, taken orally approximately 25-60 minutes prior to anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 20mg, 40mg, or 60mg, or decreased to 5mg. The maximum recommended dosing frequency is once per 24-hour period. Tablets should be swallowed whole with a glass of water; they may be taken with or without food, though high-fat meals may delay onset of action.

Precautions

Patients with cardiovascular disease should undergo stress testing before initiating therapy. Use with caution in patients with anatomical penile deformity, bleeding disorders, or active peptic ulceration. Priapism (erection lasting >4 hours) requires immediate medical attention to prevent permanent tissue damage. Sudden vision loss or hearing changes necessitate discontinuation and prompt ophthalmologic/audiologic evaluation. Avoid excessive alcohol consumption (may increase risk of hypotension).

Contraindications

Concomitant use with organic nitrates (e.g., nitroglycerin, isosorbide mononitrate) or nitric oxide donors. History of hypersensitivity to Vardenafil or any excipients. Patients with severe hepatic impairment (Child-Pugh C). Unstable angina, recent myocardial infarction, or life-threatening arrhythmias. History of non-arteritic anterior ischemic optic neuropathy (NAION). Concomitant use with potent CYP3A4 inhibitors in patients with pre-existing cardiovascular risk factors.

Possible side effects

Common (≥1/100): headache, flushing, nasal congestion, dyspepsia. Uncommon (≥1/1000): dizziness, back pain, myalgia, increased creatinine kinase. Rare: visual disturbances (bluish tinge, increased light sensitivity), hypotension, syncope, priapism. Very rare: sudden hearing loss, NAION, seizures, serious cardiovascular events. Most adverse reactions are mild to moderate and transient in nature.

Drug interaction

Contraindicated with nitrates and nitric oxide donors. Potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) significantly increase Vardenafil exposure—dose adjustment required. Alpha-blockers (e.g., doxazosin) may potentiate hypotensive effects; separate administration by 6 hours. Moderate interaction with CYP3A4 inducers (e.g., rifampicin). Grapefruit juice may increase plasma concentrations. Caution with other antihypertensives.

Missed dose

Vilitra is taken on an as-needed basis; there is no scheduled dosing regimen. If a dose is missed, it may be taken when remembered, provided sexual activity is anticipated. Do not take more than one dose within 24 hours.

Overdose

Symptoms may include severe headache, visual disturbances, syncope, prolonged erection, and hypotension. Standard supportive measures should be employed, including supine positioning with legs elevated for hypotension. Priapism requires urgent urological intervention. Hemodialysis is not expected to significantly enhance elimination due to high protein binding and extensive tissue distribution.

Storage

Store below 30°C (86°F) in original packaging. Protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date printed on packaging.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. Do not initiate or alter dosage without physician supervision. The manufacturer is not liable for misuse or incorrect interpretation of this data.

Reviews

Clinical studies demonstrate Vilitra’s efficacy, with 80% of patients reporting improved erections versus 30% on placebo. Patient satisfaction surveys indicate high rates of successful intercourse attempts and improved relationship quality. Real-world evidence supports its tolerability profile, with discontinuation rates due to adverse events below 3% in most cohorts. Long-term users report consistent therapeutic effects with appropriate dose management.